Neo Gen Screening Services

Year 2000 update

Included in our Comprehensive Newborn Screening Programs are the Following Services:

Parent brochure that describes the benenfits of newborn screening.

Comprehensive follow-up program.

Neo Gen Screening filter paper blood collection forms.

Pre-addressed, pre-paid, mailing envelopes.



Genetic Disease and Frequency Observed at Neo Gen

Genetic Diseases


Laboratory (Observed)

Amino Acid Disorders


1 : 7, 728

Fatty Acid Oxidation Defects


1 : 15, 675

Organic Acid Disorders


1 : 16, 388

Cystic Fibrosis


1 : 5, 979

Endocrine Disorders


1: 14, 630

Other Disorders

Biotinidase, Gal

1 : 33, 867



1 : 1, 777

Combined Frequency


> 1: 2,000


Cost / Benefit of Newborn Screening

Early detection of genetic diseases will result in early management and treatment with an improved outcome for most diseases screened for in our programs. This can result in lower long term health care costs and can decrease the frequency of sudden unexplained deaths or hospitalizations.

False positive rate is lower due to our modern, accurate analytical techniques. This means fewer requested repeat specimens resulting in a decrease in stress on families concerned about a possible positive result.

Newborns in your hospital, birth center, or screening program will be tested for more than 30 diseases using state-of-the-art technology at a cost that is often lower than routine screening programs in many states.

Newborn screening is good medicine and it helps everyone, especially our newest children.


2000 Update

During the year 2000, Neo Gen Screening will have tested more than one million newborns using state-of-the-art technologies such as tandem mass spectrometry (MS/MS).

During 1998 and 1999 the approximate newborn screening volume was  250,000 samples per year.

The combined frequency of disorders has remained high at 1 case per 1,500.  More than 40 newborns with MCAD deficiency have been found in our testing population which comprised Pennsylvania, North Carolina (2 year pilot program in partnership with the state of North Carolina),  and hospitals in Ohio and Illinois.  In addition, results from our autopsy screening program has revealed that 20 unexplained infant deaths were due to MCAD deficiency in over 4500 samples analyzed.



For more information about our:

Comprehensive Newborn Screening Program
Supplemental Newborn Screening Program
Clinical Diagnostic Screening & Testing
Research and Development Program
Quality Assurance & Control Program

Please contact us at:
Neo Gen Screening
ananew5.gif (731 bytes)ananew5.gif (731 bytes)

ananew5.gif (731 bytes) (voice)
ananew5.gif (731 bytes) (fax)

email for general information

President / Laboratory Director: Edwin W. Naylor, Ph.D., M.P.H.

[Home] [Info] [News] [Sales] [R&D] [Staff] [Results]

© 2000 Neo Gen Screening. All rights reserved.